Compare VRA & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRA | RFL |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 61.1M |
| IPO Year | 2010 | 2017 |
| Metric | VRA | RFL |
|---|---|---|
| Price | $2.47 | $1.46 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 154.2K | 77.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $416,097,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.39 | $1.12 |
| 52 Week High | $3.41 | $3.19 |
| Indicator | VRA | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 76.12 |
| Support Level | $1.89 | $1.41 |
| Resistance Level | $2.52 | $1.60 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 6.25 | 72.49 |
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.